New pill shows promise for severe eczema in major trial
NCT ID NCT05526222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral medication, jaktinib, for adults with moderate to severe atopic dermatitis (eczema). About 443 participants will receive either jaktinib or a placebo to see if it improves skin symptoms like redness and itching. The goal is to find a safe and effective treatment option for people whose eczema is not well controlled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
139 People's Middle Road
Changsha, Hunan, 410008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?